NASDAQ:ADAP Adaptimmune Therapeutics - ADAP Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Adaptimmune Therapeutics plc Please log in to your account or sign up in order to add this asset to your watchlist. $1.77 -0.07 (-3.80%) (As of 01/26/2023 12:00 AM ET) Add Compare Share Share Today's Range$1.77▼$1.9450-Day Range$1.25▼$2.5352-Week Range$1.01▼$3.32Volume476,465 shsAverage Volume428,539 shsMarket Capitalization$289.98 millionP/E RatioN/ADividend YieldN/APrice Target$6.00 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media Adaptimmune Therapeutics MarketRank™ ForecastAnalyst RatingModerate Buy2.60 Rating ScoreUpside/Downside239.0% Upside$6.00 Price TargetShort InterestHealthy1.87% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment1.06Based on 5 Articles This WeekInsider TradingSelling Shares$90,768 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($1.09) to ($0.78) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.24 out of 5 starsMedical Sector689th out of 1,048 stocksBiological Products, Except Diagnostic Industry110th out of 168 stocks 3.3 Analyst's Opinion Consensus RatingAdaptimmune Therapeutics has received a consensus rating of Buy. The company's average rating score is 2.60, and is based on 3 buy ratings, 2 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $6.00, Adaptimmune Therapeutics has a forecasted upside of 239.0% from its current price of $1.77.Amount of Analyst CoverageAdaptimmune Therapeutics has only been the subject of 4 research reports in the past 90 days. Previous Next 4.0 Short Interest Percentage of Shares Shorted1.87% of the float of Adaptimmune Therapeutics has been sold short.Short Interest Ratio / Days to CoverAdaptimmune Therapeutics has a short interest ratio ("days to cover") of 5.1.Change versus previous monthShort interest in Adaptimmune Therapeutics has recently decreased by 8.14%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldAdaptimmune Therapeutics does not currently pay a dividend.Dividend GrowthAdaptimmune Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ADAP. Previous Next 3.4 News and Social Media Coverage News SentimentAdaptimmune Therapeutics has a news sentiment score of 1.06. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.73 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Adaptimmune Therapeutics this week, compared to 1 article on an average week.Search InterestOnly 3 people have searched for ADAP on MarketBeat in the last 30 days. This is a decrease of -25% compared to the previous 30 days.MarketBeat Follows4 people have added Adaptimmune Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Adaptimmune Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $90,768.00 in company stock.Percentage Held by Insiders17.37% of the stock of Adaptimmune Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Adaptimmune Therapeutics are expected to grow in the coming year, from ($1.09) to ($0.78) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Adaptimmune Therapeutics is -1.62, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Adaptimmune Therapeutics is -1.62, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAdaptimmune Therapeutics has a P/B Ratio of 1.34. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Adaptimmune Therapeutics (NASDAQ:ADAP) StockAdaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States and the United Kingdom. The company's specific peptide enhanced affinity receptor (SPEAR) T-cell platform enables it to identify cancer targets. It is developing ADP-A2M4 that is in phase II clinical trials with SPEARHEAD-1 for synovial sarcoma and myxoid round cell liposarcoma indications (MRCLS); in phase II clinical trials with SPEARHEAD-2 for patients with head and neck cancer; and in phase I clinical trials for urothelial, melanoma, head and neck, ovarian, non-small cell lung, esophageal and gastric, synovial sarcoma, and MRCLS cancers. The company is also developing ADP-A2AFP, which is in phase I clinical trials for hepatocellular carcinoma; and ADP-A2M4CD8, which is in phase I clinical trial for SPEAR T-cells focusing on treating patients with lung, gastroesophageal, head and neck, ovarian, and bladder cancers. It has a collaboration and license agreement with GSK; third party collaborations with Noile-Immune Biotech Inc., Alpine Immune Sciences, Inc., and National Center for Cancer Immune Therapy in Denmark; strategic alliance agreement with the MD Anderson Cancer Center; and co-development and co-commercialization agreement with Universal Cells, Inc. Adaptimmune Therapeutics plc also has a strategic collaboration and license agreement with Genentech, Inc. and F. Hoffman-La Roche Ltd to develop personalized allogeneic T-cell therapies utilizing aß T-cell receptors. Adaptimmune Therapeutics plc was founded in 2008 and is headquartered in Abingdon, the United Kingdom.Read More Receive ADAP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Adaptimmune Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address ADAP Stock News HeadlinesJanuary 25, 2023 | americanbankingnews.comAdaptimmune Therapeutics plc (NASDAQ:ADAP) Short Interest UpdateJanuary 19, 2023 | americanbankingnews.comAdrian Rawcliffe Sells 10,057 Shares of Adaptimmune Therapeutics plc (NASDAQ:ADAP) StockJanuary 27, 2023 | Porter & Company (Ad)The Next Big Crisis Is HereYou just can’t see it yet because it’s NOT a banking, financial, or economic crisis… it’s far worse and threatens every dollar in your retirement account.January 18, 2023 | marketwatch.comAn Overview of Neuroblastoma Treatment Market, Major Participants, and Prospects by 2028January 9, 2023 | finance.yahoo.comPublication of Data from Adaptimmune's Completed Phase 1 Trial with Afami-cel in Nature Medicine Demonstrating an Acceptable Safety Profile and Encouraging Responses in Synovial SarcomaJanuary 8, 2023 | finance.yahoo.comEven after rising 48% this past week, Adaptimmune Therapeutics (NASDAQ:ADAP) shareholders are still down 72% over the past five yearsJanuary 6, 2023 | benzinga.comPneumagen appoints James Noble, a highly experienced biotech leader, as Chairman of its Board of DirectorsJanuary 5, 2023 | markets.businessinsider.comExpert Ratings for Adaptimmune TherapeuticsJanuary 27, 2023 | Porter & Company (Ad)The Next Big Crisis Is HereYou just can’t see it yet because it’s NOT a banking, financial, or economic crisis… it’s far worse and threatens every dollar in your retirement account.January 3, 2023 | markets.businessinsider.comVerismo Therapeutics Expands Quality and Compliance TeamDecember 27, 2022 | finance.yahoo.com3 Under-$10 Drug Stocks Wall Street Analysts Recommend BuyingDecember 23, 2022 | finance.yahoo.comAdaptimmune Announces Initiation of Biologics License Application (BLA) Submission for Afami-cel, Its First-Gen Engineered TCR T-cell Therapy targeting MAGE-A4, For the Treatment of Synovial SarcomaDecember 10, 2022 | finance.yahoo.comHedge funds investors may adopt severe steps after Adaptimmune Therapeutics plc's (NASDAQ:ADAP) latest 20% drop adds to a year lossesNovember 18, 2022 | finance.yahoo.comData from Cohort 1 of SPEARHEAD-1 Trial at CTOS Continue to Support BLA Submission for Afami-cel in Synovial Sarcoma - Response Rate and Durability Remain ConsistentNovember 16, 2022 | markets.businessinsider.comSVB Securities Reaffirms Their Hold Rating on ImmunoGen (IMGN)November 14, 2022 | finance.yahoo.comReCode Therapeutics Establishes Scientific Advisory BoardNovember 13, 2022 | finance.yahoo.comNew Forecasts: Here's What Analysts Think The Future Holds For Adaptimmune Therapeutics plc (NASDAQ:ADAP)November 11, 2022 | finance.yahoo.comLab notes: Adaptimmune to reduce workforce; NRx completes $11M debt financingNovember 10, 2022 | bizjournals.comVeterans of Influence Awards 2022: John Lunger, Adaptimmune TherapeuticsNovember 10, 2022 | finance.yahoo.comAdaptimmune Therapeutics Third Quarter 2022 Earnings: Beats ExpectationsNovember 8, 2022 | finance.yahoo.comAdaptimmune Therapeutics (NASDAQ:ADAP) Is In A Strong Position To Grow Its BusinessNovember 8, 2022 | finance.yahoo.comWhy Adaptimmune Therapeutics Stock Is Glowing Green TodayNovember 8, 2022 | finance.yahoo.comAdaptimmune Reports Increased Response Rate and Durability of Response in Its Phase 1 SURPASS trial; ORR Now 52% Across Ovarian, Urothelial, and Head & Neck CancersNovember 8, 2022 | finance.yahoo.comAdaptimmune Reports Third-Quarter Financial Results and Business UpdateOctober 27, 2022 | finance.yahoo.comAdaptimmune to Report Q3 2022 Financial and Business Updates on Tuesday, November 8, 2022October 25, 2022 | finance.yahoo.comAdaptimmune Enhances Its Pipeline of Wholly Owned Cell Therapies for Cancer with Transfer of PRAME and NY-ESO Target Programs from GSKSeptember 29, 2022 | marketwatch.comT-Cell Immunotherapy Market Insights : Industry dynamics, New Technologies and Forecast to 2027See More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive ADAP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Adaptimmune Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address ADAP Company Calendar Last Earnings11/08/2022Today1/27/2023Next Earnings (Estimated)3/13/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ADAP CUSIPN/A CIK1621227 Webwww.adaptimmune.com Phone441235430000Fax44-12-3543-0001Employees494Year FoundedN/APrice Target and Rating Average Stock Price Forecast$6.00 High Stock Price Forecast$10.00 Low Stock Price Forecast$3.00 Forecasted Upside/Downside+239.0%Consensus RatingModerate Buy Rating Score (0-4)2.60 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($1.09) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-158,090,000.00 Net Margins-998.26% Pretax Margin-988.49% Return on Equity-112.16% Return on Assets-43.50% Debt Debt-to-Equity RatioN/A Current Ratio4.00 Quick Ratio4.00 Sales & Book Value Annual Sales$6.15 million Price / Sales47.15 Cash FlowN/A Price / Cash FlowN/A Book Value$1.32 per share Price / Book1.34Miscellaneous Outstanding Shares163,829,000Free Float135,372,000Market Cap$289.98 million OptionableOptionable Beta2.23 Key ExecutivesMr. Adrian G. Rawcliffe (Age 51)CEO, Principal Accounting Officer & Director Comp: $1.01MDr. Helen Katrina Tayton-Martin MBA (Age 56)Ph.D., Co-Founder & Chief Bus. & Strategy Officer Comp: $709.84kMr. Gavin Hilary James Wood BA (Hons) (Age 53)ACA, Chief Financial Officer Comp: $686.96kMr. William C. Bertrand Jr. (Age 58)Esq., J.D., Chief Operating Officer Comp: $687.09kMr. John Lunger (Age 54)Chief Patient Supply Officer Comp: $645.91kMs. Joanna Brewer Ph.D.Chief Scientific OfficerDr. Juli P. Miller Ph.D.VP of Investor RelationsMs. Kerry SharpSr. VP & Gen. CouncilMr. Sébastien DesprezVP of Communications & Corp. AffairsDr. Rafael G. Amado M.D. (Age 59)Pres of R&D More ExecutivesKey CompetitorsOyster Point PharmaNASDAQ:OYSTOptheaNASDAQ:OPTAura BiosciencesNASDAQ:AURAInnate PharmaNASDAQ:IPHACabaletta BioNASDAQ:CABAView All CompetitorsInsiders & InstitutionsBaillie Gifford & Co.Bought 2,505,003 shares on 1/24/2023Ownership: 10.480%Key Client Fiduciary Advisors LLCSold 139,245 shares on 1/17/2023Ownership: 0.181%Adrian RawcliffeSold 10,057 sharesTotal: $18,706.02 ($1.86/share)John LungerSold 4,440 sharesTotal: $8,258.40 ($1.86/share)Adrian RawcliffeSold 18,763 sharesTotal: $32,084.73 ($1.71/share)View All Insider TransactionsView All Institutional Transactions ADAP Stock - Frequently Asked Questions Should I buy or sell Adaptimmune Therapeutics stock right now? 5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Adaptimmune Therapeutics in the last twelve months. There are currently 2 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" ADAP shares. View ADAP analyst ratings or view top-rated stocks. What is Adaptimmune Therapeutics' stock price forecast for 2023? 5 Wall Street research analysts have issued 1-year price targets for Adaptimmune Therapeutics' shares. Their ADAP share price forecasts range from $3.00 to $10.00. On average, they predict the company's share price to reach $6.00 in the next twelve months. This suggests a possible upside of 239.0% from the stock's current price. View analysts price targets for ADAP or view top-rated stocks among Wall Street analysts. How have ADAP shares performed in 2023? Adaptimmune Therapeutics' stock was trading at $1.46 on January 1st, 2023. Since then, ADAP shares have increased by 21.2% and is now trading at $1.77. View the best growth stocks for 2023 here. Are investors shorting Adaptimmune Therapeutics? Adaptimmune Therapeutics saw a decrease in short interest in January. As of January 15th, there was short interest totaling 2,710,000 shares, a decrease of 8.1% from the December 31st total of 2,950,000 shares. Based on an average trading volume of 536,000 shares, the days-to-cover ratio is presently 5.1 days. Approximately 1.9% of the shares of the company are short sold. View Adaptimmune Therapeutics' Short Interest. When is Adaptimmune Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, March 13th 2023. View our ADAP earnings forecast. How were Adaptimmune Therapeutics' earnings last quarter? Adaptimmune Therapeutics plc (NASDAQ:ADAP) posted its quarterly earnings data on Tuesday, November, 8th. The biotechnology company reported ($0.24) EPS for the quarter, topping analysts' consensus estimates of ($0.28) by $0.04. The biotechnology company had revenue of $7.01 million for the quarter, compared to analysts' expectations of $4.40 million. Adaptimmune Therapeutics had a negative trailing twelve-month return on equity of 112.16% and a negative net margin of 998.26%. What is Adrian Rawcliffe's approval rating as Adaptimmune Therapeutics' CEO? 6 employees have rated Adaptimmune Therapeutics Chief Executive Officer Adrian Rawcliffe on Glassdoor.com. Adrian Rawcliffe has an approval rating of 100% among the company's employees. This puts Adrian Rawcliffe in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Adaptimmune Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Adaptimmune Therapeutics investors own include Zynerba Pharmaceuticals (ZYNE), CA (CA), Endologix (ELGX), Brainstorm Cell Therapeutics (BCLI), Second Sight Medical Products (EYES), Shopify (SHOP), Micron Technology (MU), BlackRock (BLK), Cara Therapeutics (CARA) and Chipotle Mexican Grill (CMG). When did Adaptimmune Therapeutics IPO? (ADAP) raised $150 million in an initial public offering on Wednesday, May 6th 2015. The company issued 9,400,000 shares at a price of $15.00-$17.00 per share. BofA Merrill Lynch, Cowen and Company and Leerink Partners acted as the underwriters for the IPO and Guggenheim Securities was co-manager. What is Adaptimmune Therapeutics' stock symbol? Adaptimmune Therapeutics trades on the NASDAQ under the ticker symbol "ADAP." Who are Adaptimmune Therapeutics' major shareholders? Adaptimmune Therapeutics' stock is owned by many different retail and institutional investors. Top institutional investors include Baillie Gifford & Co. (10.48%), Key Client Fiduciary Advisors LLC (0.18%) and Vigilare Wealth Management (0.02%). Insiders that own company stock include Adrian Rawcliffe, Elliot Norry, Gavin Wood, James Noble, John Lunger, Lawrence M Alleva, William C Bertrand Jr and William C Bertrand, Jr. View institutional ownership trends. How do I buy shares of Adaptimmune Therapeutics? Shares of ADAP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Adaptimmune Therapeutics' stock price today? One share of ADAP stock can currently be purchased for approximately $1.77. How much money does Adaptimmune Therapeutics make? Adaptimmune Therapeutics (NASDAQ:ADAP) has a market capitalization of $289.98 million and generates $6.15 million in revenue each year. The biotechnology company earns $-158,090,000.00 in net income (profit) each year or ($1.09) on an earnings per share basis. How many employees does Adaptimmune Therapeutics have? The company employs 494 workers across the globe. How can I contact Adaptimmune Therapeutics? Adaptimmune Therapeutics' mailing address is 60 JUBILEE AVENUE MILTON PARK OXFORDSHIRE, ABINGDON X0, OX14 4RX. The official website for the company is www.adaptimmune.com. The biotechnology company can be reached via phone at 441235430000, via email at ir@adaptimmune.com, or via fax at 44-12-3543-0001. This page (NASDAQ:ADAP) was last updated on 1/27/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.